Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China
Frontiers in Pharmacology · 03.12.2024 · 15
DOI: 10.3389/fphar.2024.1468435 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 03.12.2024. Verfasst von Xiang Xiao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, West China Hospital of Sichuan University, Chengdu, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
This study aimed to investigate the association between the utilization of Sodium-dependent glucose cotransporters inhibitors (SGLT2i) in real-world settings and kidney outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) in mainland China.
Methods
In a retrospective analysis of electronic medical records from West China Hospital of Sichuan University, patients with T2D and CKD were included. Patients were divided into two groups, those initiating treatment with SGLT2i and those receiving other glucose-lowering drugs (oGLDs). The primary focus lies in examining the impact of SGLT2i on the decline slope of eGFR and major kidney events in these patients.
Results
We enrolled 944 patients diagnosed with both T2D and CKD. Out of these, 605 patients were prescribed SGLT2i, while the remaining 339 patients received oGLDs. The median follow-up duration were 16.8 months and 20.6 months, respectively. Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m 2 per year reduction compared to oGLDs, 95% CI: 4.73–5.15). A total of 101 kidney composite endpoint events occurred, with 31 events in the SGLT2i group and 70 events in the oGLDs group. The use of SGLT2i was associated with a 65% decrease in the risk of kidney composite endpoint events (hazard ratio 0.35, 95% CI 0.19–0.63).
Conclusions
In clinical practice, SGLT2i have shown favorable effects on kidney prognosis in patients with T2D and CKD in mainland China. These effects remain consistent across patients with varying risks of CKD progression. Clinical Trial Registration Number ChiCTR2300068497.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, West China Hospital of Sichuan University, Chengdu, China.
- Department of Nephrology, The first affiliated hospital of Chengdu Medical college, Chengdu, China.
- Laboratory of Diabetic Kidney Disease, Centre of Diabetes and Metabolism Research, West China Hospital of Sichuan University, Chengdu, China.
- Department of Project Design and Statistics, West China Hospital, Sichuan University, Chengdu, China.
- Department of Clinical Research Management, West China Hospital, Sichuan University, Chengdu, China.
Zitieren
APA
Xiao, X., Ji, S., Zheng, T., Wang, T., Jiang, D., & Liu, F. (2024). Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1468435
Vancouver
Xiao X, Ji S, Zheng T, Wang T, Jiang D, Liu F. Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1468435
BibTeX
@article{Xiao2024,
author = {Xiao, Xiang and Ji, Shuming and Zheng, Tao and Wang, Tianzhu and Jiang, Dapeng and Liu, Fang},
title = {Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1468435}
}
EUVIMED